BR9612093A - Anticorpo anti-idiotipo monoclonal murino 11d10 e métodos para a utilização do mesmo - Google Patents
Anticorpo anti-idiotipo monoclonal murino 11d10 e métodos para a utilização do mesmoInfo
- Publication number
- BR9612093A BR9612093A BR9612093-2A BR9612093A BR9612093A BR 9612093 A BR9612093 A BR 9612093A BR 9612093 A BR9612093 A BR 9612093A BR 9612093 A BR9612093 A BR 9612093A
- Authority
- BR
- Brazil
- Prior art keywords
- hmfg
- monoclonal anti
- idiotype antibody
- methods
- idiotype
- Prior art date
Links
- 230000003302 anti-idiotype Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 241001529936 Murinae Species 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000008105 immune reaction Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000282693 Cercopithecidae Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 235000020256 human milk Nutrition 0.000 abstract 1
- 210000004251 human milk Anatomy 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 108010071421 milk fat globule Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4725—Mucins, e.g. human intestinal mucin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Patente de Invenção: <B>''ANTICORPO ANTI-IDIOTIPO MONOCLONAL MURINO 11D10 E MéTODOS PARA A UTILIZAçãO DO MESMO''<D>. A presente invenção fornmece um anticorpo anti-idiotipo monoclonal 11D10 o qual provoca obtém uma reação imune contra um epítope especifíco de uma mucina de elevado pelo molecular de glóbulo de gordura do leite humano (HMFG) e um hidridoma o qual produz 11D10. O hibridoma que produz 11D10 foi selecionado através de procedimentos específicos. 11D10 induz uma reação imunológia a HMFG em camundongos, coelhos, macacos e pacientes com tumores avaçados associados a HMFG. Esta invenção fornece composições originais de seq³ências de polinucleotídeos condificando as regiões leve varia'vel e/ou pesada variável de anticorpo anti-idiotipo monoclonal 11D10, bem como polipeptídeos codificados pelas mesmas. A invenção também composições as quais podem ser usadas para a detecção ou tratamento de tumores associados a HMFG.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57576295A | 1995-12-20 | 1995-12-20 | |
US59196596A | 1996-01-29 | 1996-01-29 | |
US08/766,350 US6949244B1 (en) | 1995-12-20 | 1996-12-13 | Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
PCT/US1996/020757 WO1997022699A2 (en) | 1995-12-20 | 1996-12-19 | Murine monoclonal anti-idiotype antibody 11d10 an methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9612093A true BR9612093A (pt) | 1999-12-28 |
Family
ID=35657434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9612093-2A BR9612093A (pt) | 1995-12-20 | 1996-12-19 | Anticorpo anti-idiotipo monoclonal murino 11d10 e métodos para a utilização do mesmo |
Country Status (9)
Country | Link |
---|---|
US (3) | US6949244B1 (pt) |
EP (1) | EP0876486B1 (pt) |
AT (1) | ATE318312T1 (pt) |
AU (1) | AU731063B2 (pt) |
BR (1) | BR9612093A (pt) |
CA (1) | CA2239799C (pt) |
DE (1) | DE69635843T2 (pt) |
ES (1) | ES2259184T3 (pt) |
WO (1) | WO1997022699A2 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274143B1 (en) * | 1997-06-13 | 2001-08-14 | Malaya Chatterjee | Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10 |
US20020098190A1 (en) * | 1997-06-13 | 2002-07-25 | Malaya Chatterjee | Compositions and methods for treating tumors bearing HMFG and CEA antigens |
US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
AT407958B (de) * | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
JP2008521820A (ja) * | 2004-11-24 | 2008-06-26 | ヘルス リサーチ インコーポレイテッド | 免疫原性ペプチドを同定および設計するための方法 |
US20070134784A1 (en) * | 2005-12-09 | 2007-06-14 | Halverson Kurt J | Microreplicated microarrays |
WO2007089419A2 (en) * | 2006-01-30 | 2007-08-09 | Fred Hutchinson Cancer Research Center | Sequence of stro-1 antibody variable region |
US8501417B2 (en) | 2007-06-26 | 2013-08-06 | Vanderbilt University | Immunological compositions as cancer biomarkers and/or therapeutics |
DK3912643T3 (da) | 2009-02-13 | 2022-10-17 | Immunomedics Inc | Immunokonjugater med en intracellulært-spaltelig binding |
US20160095939A1 (en) | 2014-10-07 | 2016-04-07 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
WO2011068845A1 (en) | 2009-12-02 | 2011-06-09 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
CA2791918C (en) | 2010-03-05 | 2019-11-19 | Boehringer Ingelheim International Gmbh | Selective enrichment of antibodies |
CN103501825B (zh) | 2011-05-02 | 2017-03-15 | 免疫医疗公司 | 用于小体积施用的同种异型选择的抗体的超滤浓缩 |
AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
WO2017004144A1 (en) | 2015-07-01 | 2017-01-05 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
CN118001422A (zh) | 2012-12-13 | 2024-05-10 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量 |
CN106132436B (zh) | 2014-02-21 | 2021-06-15 | Ibc药品公司 | 通过诱导对trop-2表达细胞的免疫应答的疾病疗法 |
EP3110445A4 (en) | 2014-02-25 | 2017-09-27 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
CA2953567C (en) | 2014-06-24 | 2023-09-05 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
AU2016252771B2 (en) | 2015-04-22 | 2021-12-16 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells |
ES2953441T3 (es) | 2015-06-25 | 2023-11-13 | Immunomedics Inc | Combinación de anticuerpos anti-hla-dr o anti-Trop-2 con inhibidores de microtúbulos, inhibidores de parp, inhibidores de la cinasa de bruton o inhibidores de la fosfoinositida 3-cinasa mejora significativamente el resultado terapéutico en el cáncer |
WO2021054262A1 (en) * | 2019-09-20 | 2021-03-25 | Terumo Kabushiki Kaisha | Method for evaluating a coating state of either an adsorbent of a sample protein or an adsorption state of a sample protein |
EP4342497A1 (en) | 2021-05-10 | 2024-03-27 | Kawasaki Institute of Industrial Promotion | Antibody having reduced binding affinity for antigen |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
JPS54140710A (en) | 1978-03-10 | 1979-11-01 | Mitsui Toatsu Chem Inc | Anti-tumor substance and its preparation |
US4436728A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4693966A (en) | 1983-03-11 | 1987-09-15 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies from lymphocytes of patients with malignant melanoma |
US5053224A (en) | 1983-11-07 | 1991-10-01 | Hilary Koprowski | Induction of antibody response to solid tumors with anti-idiotype antibodies |
DE3479289D1 (en) | 1983-11-07 | 1989-09-14 | Wistar Inst | Immune response to tumours and viruses induced by anti-idiotype antibodies |
US5171568A (en) | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
US4675287A (en) | 1984-07-26 | 1987-06-23 | Scripps Clinic And Research Foundation | Monoclonal antibody directed to human ganglioside GD2 |
US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4918164A (en) | 1987-09-10 | 1990-04-17 | Oncogen | Tumor immunotherapy using anti-idiotypic antibodies |
US4935495A (en) | 1984-12-21 | 1990-06-19 | Oncogen | Monoclonal antibodies to the L6 glycolipid antigenic determinant found on human non-small cell lung carcinomas |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4904596A (en) | 1985-08-07 | 1990-02-27 | Fred Hutchinson Cancer Research Center | Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5009995A (en) | 1986-10-27 | 1991-04-23 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to melanoma cells |
US4996490A (en) * | 1986-11-18 | 1991-02-26 | Atlantic Richfield Company | Microwave apparatus and method for measuring fluid mixtures |
US4849509A (en) | 1987-02-20 | 1989-07-18 | The Wistar Institute | Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
WO1989007268A1 (en) | 1988-02-08 | 1989-08-10 | John Muir Cancer & Aging Institute | Monoclonal antibody specific to a novel mucin-like glycoprotein surface antigen on human carcinoma cells |
JPH01207920A (ja) | 1988-02-16 | 1989-08-21 | Oki Electric Ind Co Ltd | InP半導体薄膜の製造方法 |
GB8812137D0 (en) | 1988-05-23 | 1988-06-29 | Imp Cancer Res Tech | Antibodies |
US5242824A (en) | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
US5077284A (en) | 1988-12-30 | 1991-12-31 | Loria Roger M | Use of dehydroepiandrosterone to improve immune response |
US5407684A (en) | 1988-12-30 | 1995-04-18 | Virginia Commonwealth University | Use of DHEA as a medicinal |
US5240833A (en) | 1989-01-30 | 1993-08-31 | The Biomembrane Institute | Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides |
US5134075A (en) | 1989-02-17 | 1992-07-28 | Oncogen Limited Partnership | Monoclonal antibody to novel antigen associated with human tumors |
US5270202A (en) | 1989-11-03 | 1993-12-14 | Syamal Raychaudhuri | Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ATE149841T1 (de) | 1990-01-26 | 1997-03-15 | Immunomedics Inc | Impfstoffe gegen krebs und infektionskrankheiten |
EP0513057A1 (en) | 1990-02-01 | 1992-11-19 | Akzo Nobel N.V. | Method for culturing cells |
JPH05506447A (ja) | 1990-05-10 | 1993-09-22 | ザ ダナーファーバー キャンサー インスチチュート | β↓2―ミクログロブリンを伴い抗原供給細胞表面上で外来ペプチッドのクラスIMHC分子との会合を増進させる方法 |
US5208146A (en) | 1990-11-05 | 1993-05-04 | The Regents Of The University Of California | Murine monoclonal anti-idiotype antibodies |
EP0574395B1 (en) | 1990-11-09 | 2002-06-12 | GILLIES, Stephen D. | Cytokine immunoconjugates |
GB9105992D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
WO1993006233A1 (en) | 1991-09-19 | 1993-04-01 | Manson Lionel A | Tumor immunotherapy utilizing a method of overcoming the resistance of a progressively growing tumor |
AU5097393A (en) | 1992-08-31 | 1994-03-29 | Jenner Technologies | Stimulation of an antitumor t-cell response using anti-idiotypic antibodies |
AU5615594A (en) | 1992-11-13 | 1994-06-08 | Cancer Research Fund Of Contra Costa | Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods |
US5472693A (en) * | 1993-02-16 | 1995-12-05 | The Dow Chemical Company | Family of anti-carcinoembryonic antigen chimeric antibodies |
US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
US6274143B1 (en) | 1997-06-13 | 2001-08-14 | Malaya Chatterjee | Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10 |
ATE510847T1 (de) | 2000-11-20 | 2011-06-15 | Univ Illinois | Membrangerüstproteine |
-
1996
- 1996-12-13 US US08/766,350 patent/US6949244B1/en not_active Expired - Fee Related
- 1996-12-19 US US08/836,455 patent/US7083943B1/en not_active Expired - Fee Related
- 1996-12-19 EP EP96945090A patent/EP0876486B1/en not_active Expired - Lifetime
- 1996-12-19 BR BR9612093-2A patent/BR9612093A/pt not_active Application Discontinuation
- 1996-12-19 ES ES96945090T patent/ES2259184T3/es not_active Expired - Lifetime
- 1996-12-19 WO PCT/US1996/020757 patent/WO1997022699A2/en active IP Right Grant
- 1996-12-19 AT AT96945090T patent/ATE318312T1/de not_active IP Right Cessation
- 1996-12-19 AU AU13542/97A patent/AU731063B2/en not_active Ceased
- 1996-12-19 DE DE69635843T patent/DE69635843T2/de not_active Expired - Fee Related
- 1996-12-19 CA CA002239799A patent/CA2239799C/en not_active Expired - Fee Related
-
2005
- 2005-05-10 US US11/126,798 patent/US7399849B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69635843D1 (de) | 2006-04-27 |
AU1354297A (en) | 1997-07-14 |
WO1997022699A2 (en) | 1997-06-26 |
CA2239799C (en) | 2008-08-12 |
US6949244B1 (en) | 2005-09-27 |
US7083943B1 (en) | 2006-08-01 |
AU731063B2 (en) | 2001-03-22 |
EP0876486A2 (en) | 1998-11-11 |
EP0876486B1 (en) | 2006-02-22 |
US20060018895A1 (en) | 2006-01-26 |
US7399849B2 (en) | 2008-07-15 |
ES2259184T3 (es) | 2006-09-16 |
CA2239799A1 (en) | 1997-06-26 |
WO1997022699A3 (en) | 1997-09-04 |
DE69635843T2 (de) | 2006-10-05 |
ATE318312T1 (de) | 2006-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9612093A (pt) | Anticorpo anti-idiotipo monoclonal murino 11d10 e métodos para a utilização do mesmo | |
HK1016018A1 (en) | Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin | |
EP1135415A4 (en) | HUMANIZED ANTIBODIES AGAINST GAMMA INTERFERON | |
EP1401870A4 (en) | ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL) | |
SG161737A1 (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors | |
EP1461081A4 (en) | ANTI-CD45RB ANTIBODY FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND TRANSPLANT ABLUSION | |
RU2012102323A (ru) | Способ лечения ревматоидного артрита посредством лекарственного препарата на основе выделенного человеческого антитела или его антигенсвязывающего фрагмента | |
MX9704897A (es) | Secuencias del anticuerpo anti-idiotipo monoclonal recombinante 3h1 relacionadas con el antigeno carcinoembrionico humano. | |
DK1140170T3 (da) | Antistoffragmenter til topisk behandling af öjensygdomme | |
ATE233279T1 (de) | Spezifisch bindende agentien | |
NO991591L (no) | Rekonstituert human anti-HM1.24 antistoff | |
DE69531290D1 (de) | Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen | |
GB8925590D0 (en) | Monoclonal antibodies | |
GR3026219T3 (en) | Mouse monoclonal antibodies | |
GR850179B (pt) | ||
PE20030282A1 (es) | Anticuerpos de interleucina-1- beta | |
DK0784684T3 (da) | Rekombinante peptider afledt af Mc3 anti BA46 antistoffet, fremgangsmåder til anvendelse deraf og fremgangsmåder til humanisering af antistofpeptider | |
DK0466818T3 (da) | Monoklonalt antistof der genkender et glycoprotein fra mucin-antigen fra membranen af fedtkugler fra human mælk | |
TR199800517A2 (xx) | H�manize anti-h�men fas antikor. | |
KR870700023A (ko) | 녹농균의 E8Ag항원 및 그것에 대한 모노클로날 항체및 하이브리도마 | |
KR890016165A (ko) | 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도 | |
CY1107163T1 (el) | Συνδεδεμενα με γαγγλιοζιτη ανασυνδυασμενα αντισωματα και η χρησιμοποιηση αυτων στη διαγνωση και θεραπευτικη αγωγη ογκων | |
ES2088820A1 (es) | Anticuerpos monoclonales antineumolisina. | |
IT1254705B (it) | Anticorpi monoclonali specifici per il fattore neuronotrofico ciliare (cntf) umano ricombinante |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO DE ACORDO COM O ART. 8O DA LPI. |